PROC (Procaps) Future Price to Earnings
Despite changes in financial personnel due to audit delays, the technical staff at Procaps Group S.A. (PROC) remains stable. Business revenues rely on soft capsule patent licensing and royalties. The projected P/E valuation visualizes these trends, where 0.00 captures the magnitude of this parameter. Final efficiency is based on a combination of proprietary plants and outsourced clinical trials.
Summary analytical data breakdowns for Procaps Group Corp (PROC)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital Procaps Group S.A.|PROC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Procaps Group S.A.|PROC - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Procaps Group S.A.|PROC - Long-Term Liabilities|Company Short-Term Debt Procaps|Quick Liquidity procapsgroup.com
- financial results and valuation multiples details:
PROC - Company Net Income|Projected Future Earnings Procaps Group S.A.|PROC - Price to Earnings Ratio|Forward P/E Multiple Procaps Group SA|PROC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Procaps Group S.A.|PROC - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Procaps|PROC - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months procapsgroup.com|PROC - Earnings per share increase in current year|Earnings growth forecast for next year Procaps Group S.A.
Fundamental valuation:PROC Procaps
The cash deficit at Procaps Group S.A. (PROC), driven by restructuring and reporting delays, is amplifying the volatility of market earnings expectations. The business's expected P/E is calculated as the ratio of current market capitalization to projected income, reflecting investors' willingness to pay a premium for future growth, which allows this chart to assess the degree of optimism currently priced in or the risk of asset overvaluation.
Competitor analysis for Procaps Group S.A.
Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Future Price to Earnings Multiple|Future Price to Earnings Amphastar Pharmaceuticals, Inc. AMPH|PCRX (Pacira Pharmaceuticals) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Corp)|Aquestive Therapeutics (AQST) - Future Price to Earnings|Projected Price to Earnings Ratio scPharmaceuticals (SCPH)|TECX (Tectonic Therapeutic Inc.) - Forward P/E Multiple|Projected Price to Earnings Tonix Pharma (TNXP)|Forward P/E Multiple SXTC|Forward P/E Multiple eupraxiapharma.com (EPRX)|Future Price to Earnings BioHarvest Sciences BHST|EXOZ (invizyne.com) - Price to Expected Earnings Ratio|ORMP - Future Price to Earnings|Market Cap to Projected Earnings Entera Bio Ltd. ENTX|HYFT (MindWalk) - Projected Price to Earnings|ABVC BioPharma, Inc - Future Price to Earnings Multiple|CPIX (Cumberland Pharmaceuticals) - Forward P/E Multiple|QNTM - Forward Price to Earnings Multiple|Future Price to Earnings FibroGen (FGEN)|TELO (Telomir Pharmaceuticals Inc) - Future Price to Earnings Multiple|Future Price to Earnings Rani Therapeutics Holdings, Inc. RANI|Synergy CHC Corp. (SNYR) - Projected Price to Earnings Ratio|RLYB: Projected Price to Earnings|LEXX - Forward P/E Multiple|Pulmatrix (PULM) - Future Price to Earnings|Price to Expected Earnings Ratio PTHL (Pheton Holdings)|Projected Price to Earnings APM|LYRA: Future Price to Earnings Multiple|Future Price to Earnings Impact BioMedical Inc (IBO)|Market Cap to Projected Earnings tnfpharma.com|cbdMD - Projected Price to Earnings|Market Cap to Projected Earnings PainReform Ltd (PRFX)|Auris Medical - Forward P/E Multiple|LIPO - Forward P/E Multiple|OPTN (OptiNose, Inc.) - Projected Price to Earnings|PIRS - Market Cap to Projected Earnings|Future Price to Earnings Petros Pharmaceuticals, Inc.|Qilian International Holding Group - Price to Expected Earnings Ratio|Future Price to Earnings ACELYRIN, Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Future Price to Earnings Multiple
